Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


A novel cancer therapeutic using thrombospondin 1 in dendritic cells.

Weng TY, Huang SS, Yen MC, Lin CC, Chen YL, Lin CM, Chen WC, Wang CY, Chang JY, Lai MD.

Mol Ther. 2014 Feb;22(2):292-302. doi: 10.1038/mt.2013.236. Epub 2013 Oct 15.


RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency.

Wang ST, Chang CC, Yen MC, Tu CF, Chu CL, Peng YT, Chen DY, Lan JL, Lin CC.

Gene Ther. 2011 Apr;18(4):372-83. doi: 10.1038/gt.2010.146. Epub 2010 Nov 25.


Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.


Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Tian S, Liu Z, Donahue C, Falo LD Jr, You Z.

Mol Ther. 2012 Feb;20(2):432-42. doi: 10.1038/mt.2011.183. Epub 2011 Sep 20.


In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.

Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X, Mikkelsen RB, Fisher PB, Wang XY.

Mol Cancer Ther. 2012 Nov;11(11):2331-41. doi: 10.1158/1535-7163.MCT-12-0164. Epub 2012 Aug 15.


A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD.

Clin Cancer Res. 2009 Jan 15;15(2):641-9. doi: 10.1158/1078-0432.CCR-08-1988.


Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors.

Walsh MP, Duncan B, Larabee S, Krauss A, Davis JP, Cui Y, Kim SY, Guimond M, Bachovchin W, Fry TJ.

PLoS One. 2013;8(3):e58860. doi: 10.1371/journal.pone.0058860. Epub 2013 Mar 12.


Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.

Teramoto K, Kontani K, Fujita T, Ozaki Y, Sawai S, Tezuka N, Fujino S, Itoh Y, Taguchi O, Kannagi R, Ogasawara K.

Cancer Immunol Immunother. 2007 Mar;56(3):331-42. Epub 2006 Aug 5.


The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.


Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.

Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B, Min W.

Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul 20.


Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.

Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.

Cancer Res. 2001 Oct 15;61(20):7563-7.


An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.

Yen MC, Weng TY, Chen YL, Lin CC, Chen CY, Wang CY, Chao HL, Chen CS, Lai MD.

Cancer Gene Ther. 2013 Jun;20(6):351-7. doi: 10.1038/cgt.2013.27. Epub 2013 May 17.


Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.


Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.

Oncology. 2005;68(2-3):163-70. Epub 2005 Jul 4.


RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.

Huang B, Mao CP, Peng S, Hung CF, Wu TC.

Hum Gene Ther. 2008 Aug;19(8):763-73. doi: 10.1089/hum.2007.059.


Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.

Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, Miyagishi M, Takeda K, Kawakami Y.

J Immunol. 2011 Jul 1;187(1):27-36. doi: 10.4049/jimmunol.1002067. Epub 2011 Jun 1.


Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus.

Zhu Y, Zheng Y, Mei L, Liu M, Li S, Xiao H, Zhu H, Wu S, Chen H, Huang L.

Int J Oncol. 2013 Oct;43(4):1151-9. doi: 10.3892/ijo.2013.2027. Epub 2013 Jul 22.


Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.

Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X, Dai L, Chen X, Zhang S, Yang Y, Yu D, Wei Y, Deng H.

BMC Cancer. 2014 Jan 29;14:48. doi: 10.1186/1471-2407-14-48.

Supplemental Content

Support Center